ESTROPLAN

Manufacturer
Parnell Technologies Pty Ltd | Parnell Manufacturing Pty Ltd
Effective date
2024-05-15
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
9
Source
full-release
Hydrated at
2026-06-01 02:43:06

Label at a glance#

ProductESTROPLAN
Active ingredientcloprostenol sodium
Label structure5 sections

Label contents#

Full prescribing information#

DESCRIPTION SECTION

estroPLAN

(cloprostenol injection)

250 mcg cloprostenol/mL (equivalent to 263 mcg cloprostenol sodium/mL)

A sterile solution of a prostaglandin F2α analogue for
intramuscular injection in beef cows, lactating dairy cows,
and replacement beef and dairy heifers

DESCRIPTION SECTION

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:
estroPLAN (cloprostenol injection) is a synthetic prostaglandin analogue structurally related to prostaglandin F2α (PGF2α). Each mL of the sterile colorless aqueous solution contains 250 mcg cloprostenol (equivalent to 263 mcg cloprostenol sodium), 5.03 mg sodium citrate, 0.66 mg anhydrous citric acid, 6.76 mg sodium chloride, 1.0 mg chlorocresol, and water for injection, q.s.

chemical structure
chemical structure

INDICATIONS & USAGE SECTION

INDICATIONS FOR USE:

1. For unobserved or non-detected estrus in beef cows, lactating dairy cows,and replacement beef and dairy heifers

2. For treatment of pyometra or chronic endometritis in beef cows, lactating dairy cows, and replacement beef and dairy heifers

3. For treatment of mummified fetus in beef cows, lactating dairy cows, and replacement beef and dairy heifers

4. For treatment of luteal cysts in beef cows, lactating dairy cows, and replacement beef and dairy heifers

5. For abortion of beef cows, lactating dairy cows, and replacement beef and dairy heifers

6. For estrus synchronization in beef cows, lactating dairy cows, and replacement beef and dairy heifers

7. For use with gonadorelin to synchronize estrous cycles to allow for fixed time artificial insemination (FTAI) in lactating dairy cows

estroPLAN causes functional and morphological regression of the corpus luteum (luteolysis) in cattle. In normal, non-pregnant cycling animals, this effect on the life span of the corpus luteum usually results in estrus 2 to 5 days after treatment. In animals with prolonged luteal function (pyometra, mummified fetus, and luteal cysts), the induced luteolysis usually results in resolution of the condition and return to cyclicity. Pregnant animals may abort depending on the stage of gestation.

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION:

Two mL of estroPLAN (500 mcg cloprostenol) should be administered by INTRAMUSCULAR INJECTION using the specific dosage regimen for the indication.

Discard remaining product 180 days after first use.

1. For unobserved or non-detected estrus in beef cows, lactating dairy cows, and replacement beef and dairy heifers

Cows and heifers which are not detected in estrus, although ovarian cyclicity continues, can be treated with estroPLAN if a mature corpus luteum is present. Estrus is expected to occur 2 to 5 days following injection, at which time animals may be inseminated. Treated cattle should be inseminated at the usual time following detection of estrus. If estrous detection is not desirable or possible, treated animals may be inseminated twice at about 72 and 96 hours post-injection.

2. For treatment of pyometra or chronic endometritis in beef cows, lactating dairy cows, and replacement beef and dairy heifers

Damage to the reproductive tract at calving or postpartum retention of the placenta often leads to infection and inflammation of the uterus (endometritis). Under certain circumstances, this may progress into chronic endometritis with the uterus becoming distended with purulent matter. This condition, commonly referred to as pyometra, is characterized by a lack of cyclical estrous behavior and the presence of a persistent corpus luteum. Induction of luteolysis with estroPLAN usually results in evacuation of the uterus and a return to normal cyclical activity within 14 days after treatment. After 14 days post-treatment, recovery rate of treated animals will not be different than that of untreated cattle.

3. For treatment of mummified fetus in beef cows, lactating dairy cows, and replacement beef and dairy heifers

Death of the conceptus during gestation may be followed by its degeneration and dehydration. Induction of luteolysis with estroPLAN usually results in expulsion of the mummified fetus from the uterus. (Manual assistance may be necessary to remove the fetus from the vagina). Normal cyclical activity usually follows.

4. For treatment of luteal cysts in beef cows, lactating dairy cows, and replacement beef and dairy heifers

A cow or heifer may be noncyclic due to the presence of a luteal cyst (a single, anovulatory follicle with a thickened wall which is accompanied by no external signs and by no changes in palpable consistency of the uterus). Treatment with estroPLAN can restore normal ovarian activity by causing regression of the luteal cyst.

5. For abortion of beef cows, lactating dairy cows, and replacement beef and dairy heifers

Unwanted pregnancies can be safely and efficiently terminated from 1 week after mating until about 5 months of gestation. The induced abortion is normally uncomplicated and the fetus and placenta are usually expelled about 4 to 5 days after the injection with the reproductive tract returning to normal soon after the abortion. The ability of estroPLAN to induce abortion decreases beyond the fifth month of gestation while the risk of dystocia and its consequences increases. estroPLAN has not been sufficiently tested under feedlot conditions; therefore recommendations cannot be made for its use in heifers placed in feedlots.

6. For estrus synchronization in beef cows, lactating dairy cows, and replacement beef and dairy heifers

The luteolytic action of estroPLAN can be utilized to schedule estrus and ovulation for an individual cycling animal or a group of animals. This allows control of the time at which cycling cows or heifers can be bred. estroPLAN can be used in a breeding program with the following methods:

  • Single estroPLAN injection: Only animals with a mature corpus luteum should be treated to obtain maximum response to the single injection. However, not all cycling cattle should be treated since a mature corpus luteum is present for only 11 to 12 days of the 21-day cycle. Prior to treatment, cattle should be examined rectally and found to be anatomically normal, be nonpregnant, and have a mature corpus luteum. If these criteria are met, estrus is expected to occur 2 to 5 days following injection, at which time animals may be inseminated. Treated cattle should be inseminated at the usual time following detection of estrus. If estrous detection is not desirable or possible, treated animals may be inseminated either once at about 72 hours or twice at about 72 and 96 hours post-injection.
    With a single injection program, it may be desirable to assess the cyclicity status of the herd before estroPLAN treatment. This can be accomplished by heat detecting and breeding at the usual time following detection of estrus for a 6-day period, all prior to injection. If by the sixth day the cyclicity status appears normal (approximately 25 - 30% detected in estrus), all cattle not already inseminated should be palpated for normality, nonpregnancy, and cyclicity, then injected with estroPLAN. Breeding should then be continued at the usual time following signs of estrus on the seventh and eighth days. On the ninth and tenth days, breeding may continue at the usual time following detection of estrus, or all cattle not already inseminated may be bred either once on the ninth day (at about 72 hours post-injection) or on both the ninth and tenth days (at about 72 and 96 hours post-injection).
  • Double estroPLAN injections: Prior to treatment, cattle should be examined rectally and found to be anatomically normal, nonpregnant, and cycling (the presence of a mature corpus luteum is not necessary when the first injection of a double injection regimen is given). A second injection should be given 11 days after the first injection. In normal, cycling cattle, estrus is expected 2 to 5 days following the second injection. Treated cattle should be inseminated at the usual time following detection of estrus. If estrous detection is not desirable or possible, treated animals may be inseminated either once at about 72 hours or twice at about 72 and 96 hours following the second estroPLAN injection. Many animals will come into estrus following the first injection; these animals can be inseminated at the usual time following detected estrus. Animals not inseminated should receive a second injection 11 days after the first injection. Animals receiving both injections may be inseminated at the usual time following detection of estrus or may be inseminated either once at about 72 hours or twice at about 72 and 96 hours post second injection.

Any breeding program recommended should be completed by either:

  • observing animals (especially during the third week after injection) and inseminating or hand mating any animals returning to estrus,
    or
  • turning in clean-up bull(s) 5 to 7 days after the last injection of estroPLAN to cover any animals returning to estrus.

Management considerations for use of estroPLAN for estrus synchronization:
   A variety of programs can be designed to best meet the needs of individual management systems. A breeding program should be selected    which is appropriate for the existing circumstances and management practices. Before a breeding program is planned, the producer's    objectives must be examined and the producer must be made aware of the projected results and limitations. The producer and the
   consulting veterinarian should review the operation's breeding history, herd health, and nutritional status and agree that a breeding program
   is practical in the producer's specific situation. For any successful breeding program:

  • cows and heifers must be normal, non-pregnant, and cycling (rectal palpation should be performed);
  • cows and heifers must be in sound breeding condition and on an adequate or increasing plane of nutrition;
  • proper program planning and record keeping are essential;
  • if artificial insemination is used, it must be performed by competent inseminators using high-quality semen.

It is important to understand that estroPLAN is effective only in animals with a mature corpus luteum (ovulation must have occurred at least 5 days prior to treatment). This must be considered when breeding is intended following a single estroPLAN injection.

There is no difference in the fertility achieved following the single or double dosage regimen when breeding occurs at induced estrus or at 72 and 96 hours post-treatment. Conception rates may be lower than expected in those fixed time breeding programs employing estroPLAN alone which omit the second insemination (ie, the insemination at or near 96 hours). This is especially true if a fixed time insemination is used following a single estroPLAN injection.

7. For use with gonadorelin to synchronize estrous cycles to allow for fixed time artificial insemination (FTAI) in lactating dairy cows

Use in reproductive synchrony programs similar to the following:

  • Administer the first gonadorelin injection by intramuscular injection on Day 0.
  • Administer 2 mL of estroPLAN by intramuscular injection 6 to 8 days after the first gonadorelin injection.
  • Administer the second gonadorelin injection 30 to 72 hours after the estroPLAN injection.
  • Perform FTAI 8 to 24 hours after the second gonadorelin injection, or inseminate cows on detected estrus using standard herd practices.

WARNINGS AND PRECAUTIONS SECTION

CONTRAINDICATIONS:

Do not use this drug product in pregnant cattle, unless abortion is desired.

WARNINGS AND PRECAUTIONS:

WITHDRAWAL PERIODS AND RESIDUE WARNINGS: No milk discard or pre-slaughter drug withdrawal period is required when used according to labeling. Use of this product in excess of the approved dose may result in drug residues.

USER SAFETY WARNINGS:

Not for use in humans. Keep this and all drugs out of the reach of children.

Women of child-bearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product.

estroPLAN is readily absorbed through the skin and can cause abortion and/or bronchospasms. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.

To obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, contact Parnell at 1-800-88-PARNELL (1-800-887-2763).

ANIMAL SAFETY WARNINGS:
As with all parenteral products, careful aseptic techniques should be employed to decrease the possibility of post-injection bacterial infection. Severe localized clostridial infections associated with injection of cloprostenol injection have been reported. In rare instances, such infections have resulted in death. Aggressive antibiotic therapy should be employed at the first sign of infection at the injection site,whether localized or diffuse.

At 50 and 100 times the recommended dose, mild side effects may be detected in some cattle. These include increased uneasiness, slight frothing, and milk let-down.

CONTACT INFORMATION:

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Parnell at 1-800-88-PARNELL (1-800-887-2763). For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae

HOW SUPPLIED SECTION

HOW SUPPLIED:

20 mL and 100 mL multidose vials

STORAGE AND HANDLING SECTION

STORAGE, HANDLING, AND DISPOSAL:
1. Protect from light.
2. Store in carton.
3. Store at controlled room temperature 20°-25°C (68°-77°F).

See FDA's website www.fda.gov/safesharpsdisposal for information on safe disposal of needles and other sharps.

Made in Australia

Manufactured by:
PARNELL TECHNOLOGIES PTY. LTD.
4/476 Gardeners Road
Alexandria NSW 2015 Australia
Owner of the registered trademark estroPLAN®

Distributed by:
PARNELL U.S. 1, Inc.
7015 College Boulevard
Level 6
Overland Park, KS 66211

Approved by FDA under ANADA # 200-310

20mL & 100mL: 50423-01-February24

PRINCIPAL DISPLAY PANEL - 20 mL Vial

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

estroPLAN®

(cloprostenol injection)

250 mcg cloprostenol/mL
(equivalent to 263 mcg cloprostenol sodium/mL)

A sterile solution of prostaglandin F2α analogue for
intramuscular injection in beef cows, lactating
dairy cows, and replacement beef and dairy heifers

CAUTION: Federal law restricts this drug to use by or
on the order of a licensed veterinarian.

Approved by FDA under ANADA # 200-310

PARNELL TECHNOLOGIES PTY. LTD.4/476 Gardeners Road, Alexandria NSW 2015, Australia

Net contents: 20 mL   10 Doses

20 mL Vial Label20 mL Vial Label

Principal Display Panel - 20 mL Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

estroPLAN®

(cloprostenol injection)

250 mcg cloprostenol/mL (equivalent to
263 mcg cloprostenol sodium/mL)

A sterile solution of a prostagandin F2 αanalogue for intramuscular injection inbeef cows, lactating dairy cows, and
replacement beef and dairy heifers.

CAUTION: Federal law
restricts this drug to use
by or on the order of a
licensed veterinarian.

Approved by FDA under ANADA # 200-310

PARNELL
living SCIENCE

Net content: 20 mL
10 Doses

20 mL Carton Label20 mL Carton Label

Principal Display Panel - 100 mL Vial

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

estroPLAN®

(cloprostenol injection)

250 mcg cloprostenol/mL
(equivalent to 263 mcg cloprostenol sodium/mL)

A sterile solution of prostaglandin F2α analogue for
intramuscular injection in beef cows, lactating
dairy cows, and replacement beef and dairy heifers

CAUTION: Federal law restricts this drug to use by or
on the order of a licensed veterinarian.

Approved by FDA under ANADA # 200-310

PARNELL TECHNOLOGIES PTY. LTD.
4/476 Gardeners Road, Alexandria NSW 2015, Australia

Net contents: 100 mL 50 Doses

100 mL Vial Label100 mL Vial Label

Principal Display Panel - 100 mL Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

estroPLAN®

(cloprostenol injection)

250 mcg cloprostenol/mL (equivalent
to 
263 mcg cloprostenol sodium/mL)

A sterile solution of a prostagandin
F2α
analogue for intramuscular
injection in 
beef cows, lactating
dairy cows, and 
replacement beef
and dairy heifers.

CAUTION: Federal law restricts this drug
to use by or on the order of a licensed
veterinarian.

Approved by FDA under ANADA # 200-310

PARNELL
living SCIENCE

Net content: 100 mL
50 Doses

100 mL Carton Label100 mL Carton Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
406625cloprostenol 250 MCG per ML Injectable SolutionPSN9
631032cloprostenol 0.25 MG/ML Injectable Solution [Estroplan]SBD9
406625cloprostenol 0.25 MG/ML Injectable SolutionSCD9
631032Estroplan (as cloprostenol sodium) 250 MCG/ML Injectable SolutionSY9
631032Estroplan 0.25 MG/ML Injectable SolutionSY9

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
e2db08c6-133f-4f4f-afb4-e90a2418d6f6Product name120230320
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
ce6d5c06-3ae0-18a6-d5b3-8cd3cc0f8906Product name720210625
f52be47f-7aa7-46c0-b1fa-50c18dd50206Product name120201029
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
11ed6f83-cdd2-4637-8379-b1a1d3ae3cdeProduct name120181101
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
86c45a79-b9f0-4476-a27c-6e10db098497Product name120180125
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68504-001-01ESTROPLAN20 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION209
68504-001-01ESTROPLAN1 in 1 CARTONINJECTION, SOLUTION19
68504-001-02ESTROPLAN1 in 1 CARTONINJECTION, SOLUTION19
68504-001-02ESTROPLAN100 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION1009

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68504-001ESTROPLAN (CLOPROSTENOL SODIUM) INJECTION, SOLUTION [PARNELL TECHNOLOGIES PTY LTD]94 package rows20240517_1b3ce6fb-0493-4b22-ab53-d2d52af47267.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
cloprostenol sodiumACTIVE INGREDIENT886SAV96753
cloprostenolACTIVE MOIETY42082388323
ANHYDROUS CITRIC ACIDINACTIVE INGREDIENTXF417D3PSL3
CHLOROCRESOLINACTIVE INGREDIENT36W53O71093
sodium chlorideINACTIVE INGREDIENT451W47IQ8X3
sodium citrateINACTIVE INGREDIENT1Q73Q2JULR3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68504-00168504-001-01, 68504-001-02

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 197 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / RECTALNAExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, SOLUTION / INTRAMUSCULAR25 mgExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / ORAL1126 mgExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / INTRACARDIAC25 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSPRAY / NASAL5 mgExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIAL1.35 mgExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSPRAY, METERED / NASAL1.2 mg/1mlExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION, EXTENDED RELEASE / ORAL62 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / PERINEURAL0.02 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / INFILTRATION0.02 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XGEL / TOPICAL0.18 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRATHECAL1.35 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XDROPS / OPHTHALMIC0.08 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XGEL / OPHTHALMIC0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSHAMPOO / TOPICAL0.07 %w/wExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLTABLET, CHEWABLE / ORAL4 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLFILM / BUCCAL9 mgExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRAMUSCULAR26 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / ENDOTRACHEAL68 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INFILTRATION648 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS0.68 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION/ DROPS / ORAL15 mgExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRALESIONAL13 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / PARENTERAL210 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION/ DROPS / TOPICAL0.23 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / EPIDURAL3535 mgExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLTABLET, CHEWABLE, EXTENDED RELEASE / ORAL12 mgExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAPERITONEAL0.54 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / PERIDURAL8.07 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAVESICAL351 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION/ DROPS / AURICULAR (OTIC)3 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / SUBCUTANEOUS1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / SUBCUTANEOUS0.8 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUSNAExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLFILM / SUBLINGUAL11 mgExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XPOWDER, DENTIFRICE / DENTAL0.03 mg/mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRAVENOUS28773 mgExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLCONCENTRATE / INTRAVENOUSADJ PHExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XPOWDER, FOR SUSPENSION / ORAL98 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / ORAL148 mgExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLSOLUTION, CONCENTRATE / INTRAVENOUS60 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLLOTION / TOPICAL211 mgExact identifier — unii candidate
61 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLAEROSOL / TOPICAL0.08 %w/wExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / INTRATYMPANIC2 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INFILTRATION3535 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAVENOUS90 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION/ DROPS / TOPICAL0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRAVENOUS0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XTABLET / ORAL231 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / AURICULAR (OTIC)0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XENEMA / RECTAL0.7 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRATHECAL131 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRA-ARTERIAL278 mgExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLOIL / TOPICAL2 mgExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / INTRAMUSCULAR9 mgExact identifier — unii candidate
134 equally ranked IID candidates
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLTABLET, EXTENDED RELEASE / ORAL312 mgExact identifier — unii candidate
61 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / RESPIRATORY (INHALATION)108 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR226 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / RETROBULBAR648 mgExact identifier — unii candidate
134 equally ranked IID candidates
CHLOROCRESOLCHLOROCRESOL36W53O7109CREAM, AUGMENTED / TOPICAL0.1 %w/wExact identifier — unii candidate
2 equally ranked IID candidates

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.